|
|
|
|
|
|
|
|
||
|
|||||||
|
|||||||
 |
| ASPREVA PHARMACEUTICALS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING AT US$11.00 (C$13.68) PER SHARE |
 |
| March 03, 2005 - Victoria B.C., Canada
Aspreva Pharmaceuticals Corporation (Nasdaq: ASPV; TSX: ASV) today announced the initial public offering of 7,200,000 shares of its common shares at a price of US$11.00 (C$13.68) per share.=20 The shares will be listed on the Nasdaq National Market under the trading symbol ASPV and the Toronto Stock Exchange under the trading symbol ASV. The Company has granted the underwriters an option to purchase up to an additional 1,080,000 common shares to cover over-allotments, if any. The underwriting syndicate is led by Merrill Lynch & Co., co-led by Banc of America Securities LLC, and co-managed by Pacific Growth Equities LLC and BMO Nesbitt Burns Inc. This offering is being made solely by means of a prospectus. A copy of the US final prospectus relating to this offering may be obtained from Merrill Lynch & Co., 4 World Financial Center, New York, NY, 10080, phone (212)449-1000, Banc of America Securities, Capital Markets Operations (Prospectus Fulfillment), DL-ProspectusDistribution@bofasecurities.com, phone (646)733-4166, or Pacific Growth Equities, LLC, One Bush Street, San Francisco, CA, 94104, phone (415)274-6800. A copy of the Canadian final prospectus may be obtained from BMO Nesbitt Burns Inc., 1 First Canadian Place, Toronto, Ontario, M5X 1H3, phone (416)363-6996. In the United States, a registration statement relating to these securities was declared effective by the Securities and Exchange Commission on March 3, 2005. In Canada, a receipt for a final prospectus was issued on behalf of the securities regulatory authorities in each of the provinces of Canada. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such province, state or other jurisdiction. About Aspreva Pharmaceuticals Corporation Aspreva Pharmaceuticals is an emerging pharmaceutical company focused on identifying, developing and commercializing new indications for approved drugs and drug candidates for underserved patient populations. For further information please contact: Sage Baker Director, Corporate Communications Aspreva Pharmaceuticals 250-744-2488 ext. 270 sbaker@aspreva.com Brian Aronson Sprout Group 11 Madison Avenue, 13th Floor New York, NY 10010 Phone: 212-538-1068 eFax: 646-935-7984 brian.aronson@sproutgroup.com |